Article

Positive results for aflibercept for mCNV reported

Regeneron Pharmaceuticals Inc. and Bayer HealthCare reported positive top-line results for aflibercept injection (Eylea) from the phase III MYRROR study in myopic choroidal neovascularization (mCNV).

Tarrytown, NY and Berlin-Regeneron Pharmaceuticals Inc. and Bayer HealthCare reported positive top-line results for aflibercept injection (Eylea) from the phase III MYRROR study in myopic choroidal neovascularization (mCNV).

Patients receiving aflibercept at an initial dose of 2 mg, followed by treatment on an as-needed basis, had a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared with a loss of 2 letters in patients receiving sham injections (p < 0.0001).

The most common adverse events observed in the MYRROR trial (that occurred with a frequency of 2% or more) were conjunctival hemorrhage, dry eye, eye pain, headache, and nasopharyngitis.

"Effective treatment options are urgently needed for patients with mCNV," said Kemal Malik, MD, a member of the Bayer HealthCare Executive Committee and head of global development. "We are pleased that the results of this study demonstrate that [aflibercept] may provide a treatment option for these patients."

In a related matter, The National Institute for Health and Care Excellence in the United Kingdom announced that aflibercept solution for injection should be recommended for the treatment of patients with wet age-related macular degeneration. Aflibercept is the first new medicine in ophthalmology to be fast-tracked to draft Final Appraisal Determination, without the need for additional consultation.

This decision means that eligible patients in England and Wales will have an alternative treatment available to them, which has been shown in two clinical studies to work as well as current treatment, but requires fewer hospital visits, reducing the burden for patients, relatives, and the National Health Service.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.